Maintenance therapy with Xpovio may extend PFS in some endometrial cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with Xpovio (selinexor) following systemic therapy may prolong progression-free survival, according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology Plenary Series.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR pathway mutation who had received at least one prior line of therapy, yielded a 33% confirmed objective response rate in efficacy-evaluable patients, and a disease control rate of 83%, according to clinical data from phase II trial (FTH-PIK-201; NCT06463028; GOG-311). 
The FDA has granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an investigational folate receptor alpha-directed, TOPO1-inhibitor antibody-drug conjugate, for the treatment of adult patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login